Virios Therapeutics (VIRI) Stock Price, News & Analysis

Company Overview

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Key Stats

• Today's Range: $1.76 to $3.03
• 50-Day Range: $0.14 to $4.99
• 52-Week Range: $0.13 to $1.04
• Volume: 637,000 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $50.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

Virios Therapeutics Stock Analysis - MarketRank™

Virios Therapeutics scored higher than 15% of companies evaluated by MarketBeat, and ranked 906th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Virios Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Virios Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Virios Therapeutics are expected to grow in the coming year, from ($0.22) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Virios Therapeutics is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Virios Therapeutics is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Virios Therapeutics has a P/B Ratio of 13.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VIRI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virios Therapeutics does not currently pay a dividend.

Dividend Growth

Virios Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for VIRI.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.13

News Sentiment

Virios Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Virios Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virios Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.05% of the stock of Virios Therapeutics is held by institutions.

VIRI Stock Analysis - Frequently Asked Questions

How have VIRI shares performed this year?

Virios Therapeutics' stock was trading at $0.5750 at the start of the year. Since then, VIRI shares have increased by 352.2% and is now trading at $2.60.
View the best growth stocks for 2024 here.

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02.

When did Virios Therapeutics IPO?

Virios Therapeutics (VIRI) raised $30 million in an IPO on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virios Therapeutics?

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Virios Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virios Therapeutics investors own include Meta Platforms (META), AMC Entertainment (AMC), SNDL (SNDL), CISO Global (CISO), Canoo (GOEV), Mullen Automotive (MULN) and Organigram (OGI).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VIRI
• CUSIP: N/A
• CIK: 1818844
• Web: www.virios.com
• Phone: 866-620-8655
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +15.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,300,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -130.33%
• Return on Assets: -115.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.27
• Quick Ratio: 7.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 13.00

Miscellaneous

• Outstanding Shares: 19,258,000
• Free Float: 16,909,000
• Market Cap: $50.07 million
• Optionable: Optionable
• Beta: 1.58